ArticleTranslational oncology2025
A CEBPB/TYMP/GDF15 signaling axis mediates tumor growth and cisplatin resistance in bladder cancer.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Investigating the mechanisms of PhIP-induced colorectal cancer through network toxicology, machine learning, and molecular dynamics simulation.Translational cancer research · 2026Article
- Molecular Insights from Differential Proteomic Profiling of Premalignant Cervical Lesions and Cervical Cancer.Pathogens (Basel, Switzerland) · 2026Article
- Integrated Multi-Omics Analyses Identify TYMP as a Candidate Protective Immunoregulatory Marker in CD4⁺ T Cells During Sepsis.Journal of inflammation research · 2026Article
- Hypoxia-Induced TGFBI Promotes Bladder Cancer Progression by Creating a Stemness Regulation Loop through Stabilizing the Disulfide Bonds of GDF15.Research (Washington, D.C.) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin-based chemotherapy remains the standard treatment for muscle-invasive bladder cancer (BC), yet resistance significantly limits its long-term efficacy. Reliable biomarkers for prognosis and therapeutic guidance are also lacking. Here, we identify thymidine phosphorylase (TYMP) as an independent prognostic risk factor that promotes BC progression and mediates cisplatin resistance. Bioinformatic analyses of TCGA and GEO datasets revealed elevated TYMP expression in BC tissues, correlating with poor patient outcomes. Functional studies in UMUC3, T24, and MB49 cell lines, as well as in syngeneic mouse models, demonstrated that TYMP knockdown suppressed BC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT), while enhancing cisplatin sensitivity. Pharmacological inhibition of TYMP using TAS-102 significantly augmented cisplatin-induced cytotoxicity in vivo. Mechanistically, the transcription factor CEBPB directly bound to and activated the TYMP promoter, thereby upregulating GDF15 expression and driving tumor growth and chemoresistance. TYMP expression positively correlated with both CEBPB and GDF15 levels in public datasets. Collectively, our findings define a CEBPB/TYMP/GDF15 signaling axis that fosters BC progression and cisplatin resistance and highlight TYMP as a novel prognostic biomarker and potential therapeutic target, with TAS-102 offering a promising strategy for overcoming cisplatin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.